CL King Initiates Coverage on Integra LifeSciences (NASDAQ:IART)

Investment analysts at CL King started coverage on shares of Integra LifeSciences (NASDAQ:IART) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $50.00 price target on the life sciences company’s stock. CL King’s price objective points to a potential upside of 27.16% from the stock’s current price.

Other research analysts also recently issued reports about the stock. Morgan Stanley decreased their target price on shares of Integra LifeSciences from $44.00 to $37.00 and set an “underweight” rating for the company in a research report on Thursday, October 26th. Truist Financial cut their price objective on shares of Integra LifeSciences from $41.00 to $39.00 and set a “hold” rating for the company in a report on Thursday, October 26th. StockNews.com raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday. Finally, JMP Securities cut their price objective on shares of Integra LifeSciences from $65.00 to $60.00 and set an “outperform” rating for the company in a report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences has a consensus rating of “Hold” and an average price target of $45.63.

Integra LifeSciences Trading Up 0.3 %

NASDAQ:IART opened at $39.32 on Tuesday. Integra LifeSciences has a 12 month low of $33.44 and a 12 month high of $60.69. The firm has a fifty day simple moving average of $37.95 and a 200-day simple moving average of $41.56. The company has a current ratio of 2.89, a quick ratio of 1.86 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $3.07 billion, a P/E ratio of 32.50, a PEG ratio of 1.51 and a beta of 1.18.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, October 25th. The life sciences company reported $0.76 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.02). The company had revenue of $382.40 million for the quarter, compared to analyst estimates of $387.22 million. Integra LifeSciences had a return on equity of 15.28% and a net margin of 6.54%. The company’s quarterly revenue was down .7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. On average, equities research analysts anticipate that Integra LifeSciences will post 3.11 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. grew its stake in Integra LifeSciences by 8,208.4% during the 1st quarter. Victory Capital Management Inc. now owns 1,230,064 shares of the life sciences company’s stock valued at $70,618,000 after acquiring an additional 1,215,259 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in Integra LifeSciences during the 3rd quarter valued at about $43,034,000. Select Equity Group L.P. purchased a new stake in Integra LifeSciences during the 4th quarter valued at about $47,199,000. Norges Bank purchased a new stake in Integra LifeSciences during the 4th quarter valued at about $39,872,000. Finally, Assenagon Asset Management S.A. purchased a new stake in Integra LifeSciences during the 3rd quarter valued at about $25,443,000. Hedge funds and other institutional investors own 84.13% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.